- Conditions
- Seizures
- Interventions
- Cannabidiol Oral Solution
- Drug
- Lead sponsor
- INSYS Therapeutics Inc
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 10
- States / cities
- San Francisco, California • Miami, Florida • Pensacola, Florida + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,207
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myelodysplasia, Leukemia
- Interventions
- chemotherapy
- Drug
- Lead sponsor
- Brown University
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Gout
- Interventions
- High Dose Colchicine (4.8 mg total dose), Low Dose Colchicine (1.8mg total dose), Placebo Control
- Drug · Other
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more
- Conditions
- Cocaine Addiction, Cocaine Abuse, Cocaine Dependence, Substance Abuse
- Interventions
- Placebo, Doxazosin
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
- Interventions
- SPR720, Placebo, Open-label Standard of Care
- Drug
- Lead sponsor
- Spero Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Altamonte Springs, Florida • Atlantis, Florida • Clearwater, Florida + 6 more
- Conditions
- Asthma
- Interventions
- Placebo, tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,071 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 21
- States / cities
- Huntington Beach, California • Mission Viejo, California • San Diego, California + 17 more
- Conditions
- Pterygium
- Interventions
- RMP-A03 - Dose 1, RMP-A03 - Dose 2, RMP-A03 Placebo
- Drug
- Lead sponsor
- Suzhou Raymon Pharmaceuticals Company, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Glendale, California • Inglewood, California • Newport Beach, California + 3 more
- Conditions
- Heart Defects, Congenital
- Interventions
- Dexrazoxane
- Drug
- Lead sponsor
- Medical City Children's Hospital
- Other
- Eligibility
- 1 Day to 6 Months
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Low-Grade Glioma, Recurrent Low-Grade Glioma, Progressive Low-Grade Glioma
- Interventions
- Mirdametinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 24 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Interventions
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
- Conditions
- Schizophrenia
- Interventions
- SPD489 low dose range (40mg, 80mg, and 100mg), SPD489 high dose range (120mg, 140mg and 160mg), Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 4
- States / cities
- Miami Springs, Florida • O'Fallon, Missouri • Saint Charles, Missouri + 1 more
- Conditions
- Chronic Pain
- Interventions
- SynchroMed Infusion System and Intrathecal Morphine Sulfate, Conventional Medicine
- Device · Other
- Lead sponsor
- MedtronicNeuro
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 6
- States / cities
- Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more
- Conditions
- Treatment Resistant Depression
- Interventions
- CERC-501, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Wichita, Kansas • Philadelphia, Pennsylvania + 1 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Genetic · Drug
- Lead sponsor
- Vector Y Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 3 more
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
- Drug
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 5
- States / cities
- Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Interventions
- Placebo, PIZV
- Drug · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
- Conditions
- Sickle Cell Disease, Sickle-Cell; Hb-SC, Sickle Beta 0 Thalassemia
- Interventions
- IMR-687, Placebo Oral Capsule
- Drug
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Participants
- Interventions
- AZD5462, Midazolam, Rosuvastatin, Digoxin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr
- Drug
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 495 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Venous Leg Ulcers
- Interventions
- Nexagon® Low Dose, Nexagon® High Dose, Nexagon® Vehicle
- Drug
- Lead sponsor
- OcuNexus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Castro Valley, California + 15 more
- Conditions
- Glaucoma, Open-Angle, Ocular Hypertension
- Interventions
- High Dose Device, Low Dose Device, Placebo Device
- Drug · Device
- Lead sponsor
- Vistakon Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 4
- States / cities
- Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more
- Conditions
- Cervical Radiculopathy
- Interventions
- cervical interlaminar with lidocaine, cervical interlaminar with normal saline, Lidocaine, Triamcinolone Acetonide, Normal saline
- Procedure · Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Mucopolysaccharidosis I
- Interventions
- JR-171 (lepunafusp alfa)
- Drug
- Lead sponsor
- JCR Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 0 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 834 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 17 more